Form 4: GoodRx Officer's Stock Activity

GoodRx Chief Accounting Officer Romin Nabiey reported the vesting of restricted stock units and a related tax-driven share disposition.

Summary

• Chief Accounting Officer Romin Nabiey reported transactions on August 15, 2025.
• Acquired 4,804 shares of Class A Common Stock through the vesting of Restricted Stock Units.
• Disposed of 1,719 shares of Class A Common Stock at $3.54 per share, likely for tax withholding.
• Following these transactions, Nabiey beneficially owns 137,292 shares of Class A Common Stock and 67,258 Restricted Stock Units.
• The Restricted Stock Units vest 6.25% on May 15, 2025, with the remaining 93.75% vesting in approximately equal quarterly installments over 15 quarters.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing indicates routine executive compensation activity, with an officer increasing their direct share count through vesting, albeit with a portion sold for taxes. It doesn't suggest any negative operational or financial issues.

Positives

• Officer Romin Nabiey's continued beneficial ownership of a significant number of shares and RSUs aligns his interests with shareholders.
• The vesting of RSUs indicates the fulfillment of compensation agreements, potentially reflecting performance milestones.

Negatives

• The disposition of 1,719 shares, while common for tax purposes, represents a reduction in direct ownership.

Future Outlook

The filing details a pre-scheduled vesting of Restricted Stock Units and does not provide forward-looking statements or guidance regarding company performance or strategy.

Industry Context

This Form 4 filing reflects routine executive compensation activity within the healthcare technology sector. Such transactions are common for officers receiving equity-based compensation and do not typically indicate broader industry trends or competitive shifts.

Comparison to Industry Standards

• Executive equity compensation, including Restricted Stock Units (RSUs) with vesting schedules and tax-related share dispositions, is a standard practice across publicly traded companies, particularly in the technology and healthcare sectors.
• The reported transactions are consistent with typical compensation structures for senior executives, similar to those observed at companies like Teladoc Health (TDOC) or Amwell (AMWL), where equity awards are a significant component of total compensation.

Stakeholder Impact

• Shareholders: The transactions are routine and reflect standard executive compensation, aligning management's interests with shareholders through equity ownership.
• Employees: No direct impact on general employees is indicated.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated.

Next Steps

• Future quarterly vesting of the remaining 67,258 Restricted Stock Units over 15 quarters.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation (RSU vesting and tax-related sales). It does not provide new information about the company's financial performance, strategic direction, or operational health that would warrant a change in investment recommendation. The transactions are expected and do not signal any significant positive or negative developments for the stock.

Keywords

GoodRx, GDRX, SEC Form 4, Insider Trading, Stock Vesting, Restricted Stock Units, Executive Compensation, Romin Nabiey, Chief Accounting Officer